product name Hexamethonium Bromide
Description: Hexamethonium Bromide is a selective antagonist of neuronal-type nicotinic AChR in ganglia. Hexamethonium Bromide is effective against Ach and carbachol (CCh) on the amplitude of endplate responses of rat omohyoid muscle with EC50 of 300 μM and 100 μM, respectively. Hexamethonium Bromide is also a weak inhibitor of acetylcholinesterase activity in rat muscle homogenates with EC50 of 1.5 mM.
References: Br J Pharmacol. 1984 Mar;81(3):519-31; Br J Pharmacol. 1997 Nov;122(6):1025-34.
362.19
Formula
C12H30N2.2Br
CAS No.
55-97-0
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: <1 mg/mL
Water: 73 mg/mL (201.55 mM)
Ethanol: <1 mg/mL
Solubility (In vivo)
Synonyms
other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/19392907
| In Vitro |
In vitro activity: Hexamethonium Bromide is effective against Ach and carbachol (CCh) on the amplitude of endplate responses of rat omohyoid muscle with EC50 of 300 μM and 100 μM, respectively. Hexamethonium Bromide (50-200 μM) causes an increase in the amplitude of nerve-evoked endplate currents (e.p.cs) recorded in the presence of 0.6 μM tubocurarine. Hexamethonium Bromide is also a weak inhibitor of acetylcholinesterase activity in rat muscle homogenates with EC50 of 1.5 mM. Hexamethonium Bromide (200 μM) decreases the time constant of decay of both endplate currents (e.p.cs) (by ~25%) and miniature endplate currents (m.e.p.cs) (by ~20%) in the rat hemi-diaphragm muscle. At low frequencies of stimulation (0.5-2 Hz), Hexamethonium Bromide (200 μM) increases e.p.c. quantal content by 30-40%. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | |
| Animal model | |
| Formulation & Dosage | |
| References | Br J Pharmacol. 1984 Mar;81(3):519-31; Br J Pharmacol. 1997 Nov;122(6):1025-34. |
Related Posts
product name Hexamethonium Bromide
Description: Hexamethonium Bromide is a selective antagonist of neuronal-type nicotinic AChR in ganglia. Hexamethonium Bromide is effective against Ach and carbachol (CCh) on the amplitude of endplate responses of rat omohyoid muscle with EC50 of 300 μM and 100 μM, respectively. Hexamethonium Bromide is also a weak inhibitor of acetylcholinesterase activity in rat muscle homogenates with EC50 of 1.5 mM.
References: Br J Pharmacol. 1984 Mar;81(3):519-31; Br J Pharmacol. 1997 Nov;122(6):1025-34.
362.19
Formula
C12H30N2.2Br
CAS No.
55-97-0
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: <1 mg/mL
Water: 73 mg/mL (201.55 mM)
Ethanol: <1 mg/mL
Solubility (In vivo)
Synonyms
other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/19392907
| In Vitro |
In vitro activity: Hexamethonium Bromide is effective against Ach and carbachol (CCh) on the amplitude of endplate responses of rat omohyoid muscle with EC50 of 300 μM and 100 μM, respectively. Hexamethonium Bromide (50-200 μM) causes an increase in the amplitude of nerve-evoked endplate currents (e.p.cs) recorded in the presence of 0.6 μM tubocurarine. Hexamethonium Bromide is also a weak inhibitor of acetylcholinesterase activity in rat muscle homogenates with EC50 of 1.5 mM. Hexamethonium Bromide (200 μM) decreases the time constant of decay of both endplate currents (e.p.cs) (by ~25%) and miniature endplate currents (m.e.p.cs) (by ~20%) in the rat hemi-diaphragm muscle. At low frequencies of stimulation (0.5-2 Hz), Hexamethonium Bromide (200 μM) increases e.p.c. quantal content by 30-40%. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | |
| Animal model | |
| Formulation & Dosage | |
| References | Br J Pharmacol. 1984 Mar;81(3):519-31; Br J Pharmacol. 1997 Nov;122(6):1025-34. |